According to Lundy Fields, formerly Regent Medical Americas president and now Mölnlycke Health Care
The companys two strategic divisions will be Surgical and Wound Care. Focusing on prevention of surgically-related infections for both patients and healthcare workers, the Surgical Division will encompass a leading manufacturer and supplier of powder-free surgical gloves (Biogel® surgical gloves) and a leading supplier of skin cleanser (Hibiclens® and Hibistat® antiseptics). A leader in trauma and pain management, the Wound Care Divisions market dynamics are driven by an aging population, higher incidence of pressure ulcers and increased home treatment.
There are clear synergies between the companies in terms of sales force and distribution as well as in R&D; this, together with a more decentralized approach by management, will see the opportunities for cost savings, increased profitability and an accelerated top line growth.
Commenting on the new strategy, Mölnlycke CEO John Samuel said, The platform for future growth is in place and now it is time for us to focus on improving and expanding our business. Our strategy is two-fold: In Surgical, we plan to take advantage of the growing market need for single use products and further expand geographically; and in Wound Care, we plan to grow the advanced wound care business from the strong base of the market leading Safetac® technology both with innovative new products and further geographical spread.